If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-21. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
==== Low-level laser therapy (LLLT) ==== Low-level laser therapy or photobiomodulation is also referred to as red light therapy and cold laser therapy. It is a non-invasive treatment option. LLLT is shown to increase hair density and growth in both genders. The types of devices (hat, comb, helmet) and duration did not alter the effectiveness, with more emphasis to be placed on lasers compared to LEDs. Ultraviolet and infrared light are more effective for alopecia areata, while red light and infrared light is more effective for androgenetic alopecia. Medical reviews suggest that LLLT is as effective or potentially more than other non invasive and traditional therapies like minoxidil and finasteride but further studies such as RCTs, long term follow up studies, and larger double blinded trials need to be conducted to confirm the initial findings.
The pericardial cavity (surrounding the heart), pleural cavity (surrounding the lungs) and peritoneal cavity (surrounding most organs of the abdomen) are the three serous cavities within the human body. While serous membranes have a lubricative role to play in all three cavities, in the pleural cavity it has a greater role to play in the function of breathing. The serous cavities are formed from the intraembryonic coelom and are basically an empty space within the body surrounded by serous membrane. Early in embryonic life visceral organs develop adjacent to a cavity and invaginate into the bag-like coelom. Therefore, each organ becomes surrounded by serous membrane - they do not lie within the serous cavity. The layer in contact with the organ is known as the visceral layer, while the parietal layer is in contact with the body wall.
Plant and fungal cells are also electrically excitable. The fundamental difference from animal action potentials is that the depolarization in plant cells is not accomplished by an uptake of positive sodium ions, but by release of negative chloride ions. In 1906, J. C. Bose published the first measurements of action potentials in plants, which had previously been discovered by Burdon-Sanderson and Darwin. An increase in cytoplasmic calcium ions may be the cause of anion release into the cell. This makes calcium a precursor to ion movements, such as the influx of negative chloride ions and efflux of positive potassium ions, as seen in barley leaves. The initial influx of calcium ions also poses a small cellular depolarization, causing the voltage-gated ion channels to open and allowing full depolarization to be propagated by chloride ions. Some plants (e.g. Dionaea muscipula) use sodium-gated channels to operate plant movements and "count" stimulation events to determine if a threshold for movement is met. Dionaea muscipula, also known as the Venus flytrap, is found in subtropical wetlands in North and South Carolina. When there are poor soil nutrients, the flytrap relies on a diet of insects and animals. Despite research on the plant, there lacks an understanding behind the molecular basis to the Venus flytraps, and carnivore plants in general. However, plenty of research has been done on action potentials and how they affect movement and clockwork within the Venus flytrap.
== History and discovery == The discovery for aggrecanases initially came from the study of cartilage and the way it degraded depending on it conditions. Scientists were attempting to find the difference in cartilage from its normal state to its diseased state. The initial analysis determined the matrix metalloproteinases could cleave the cartilage at a specific site. The site as within the interlobular domain it was in between the G1 and G2 regions. Upon further experimentation in 1991, the cartilage was treated with interleukin-1, an inflammatory mediator. This went against the initial findings because the split happened in a new location. This new discovery allowed scientist to understand there was another enzyme that was responsible, aggrecanase. Through further experimentation aggrecanse was continually detected particularly in relation to inflammatory arthritis and osteoarthritis. The first successfully identified enzyme was ADAMTS4, an aggrecanase. As time went on the enzyme was determined to be a part of a zinc dependent family, the ADAMTS family. More enzymes were discovered, ADAMTS5 and ADAMRS1. All of the enzymes in the ADAMTS family were exhibiting similar activity. They were all functioning within the cartilage as mediators.
Sources: en.wikipedia.org
Reporter genes are molecular tools widely used in molecular biology, genetics, and biotechnology to study gene function, expression patterns, and regulatory mechanisms. These genes encode proteins that produce easily detectable signals, such as fluorescence, luminescence, or enzymatic activity, allowing researchers to monitor cellular processes in real-time. Reporter genes are often fused to regulatory sequences of genes of interest, enabling scientists to analyze promoter activity, transcriptional regulation, and signal transduction pathways. Common reporter gene systems include green fluorescent protein (GFP), β-galactosidase (lacZ), luciferase, and chloramphenicol acetyltransferase (CAT), each offering distinct advantages depending on the experimental application. Their versatility makes reporter genes invaluable in fields such as drug discovery, gene therapy, and synthetic biology.
=== Polonium === Polonium is produced in reactors from natural 209Bi, bombarded with neutrons, creating 210Bi, which then decays to 210Po via beta-minus decay. The final purification is done pyrochemically with sodium hydroxide at 500 °C. This is then followed by liquid-liquid extraction, with dibutyl Carbitol as the extractant.
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 28 August A Short History of the Future: Spaceship, how space ships were viewed at cinema, and that the US space programme was largely started by Wernher von Braun, when making documentary programmes at Walt Disney; the American public needed to be convinced of the possibilities of space travel - as it would be publicly funded; Jesco Von Puttkamer of NASA; technology historical writer Frederick I. Ordway III; von Braun had first attempted a rocket launch in 1937, but it exploded; on 3 October 1942, his first successful rocket was the first man-made supersonic craft; there were 3,165 V-2 successful launches during the war; much 1950s popular space diagrams were drawn by Chesley Bonestell, which drew the attention of Walt Disney and producer Ward Kimball, who subsequently made the 1955 television episodes Man in Space and Man and the Moon, featuring Wernher von Braun, where von Braun demonstrated his XR-1 craft; health effects of space were demonstrated by former Luftwaffe fighter pilot and physicist Heinz Haber, later a well-known German television presenter; Star Trek: The Original Series was not popular when first shown, but was hugely popular after 1972 when it was repeated; consequently, the first space shuttle was named Enterprise, and when the shuttle was displayed in California on 17 September 1976, it was attended by the full cast of Star Trek, with the theme music also being played; Beverly Thurmond, NASA food scientist; Laura Louviere of NASA.
== Awards == Major Awards 1. Young Scientist Medal (1988), by the Indian Science Congress Association, India. 2. INSA Young Scientist Medal (1991), by the Indian National Science Academy, New Delhi. 3. CRSI Bronze Medal (2002), by the Chemical Research Society of India. 4. MRSI Medal (2007), by Material Research Society of India. 5. Shanti Swarup Bhatnagar Prize (2007), awarded by CSIR, Govt. India. 6. DAE Outstanding Researcher Award (2009), awarded by Dept. Atomic Energy, Govt. India. 7. Thomson Reuters Research Excellence-India Research Front Award (2009). 8. The Infosys Prize for Physical Sciences 2012 by Infosys Science Foundation. 9. Khwarizmi International Award 2012 by Iranian Organisation for Science and Technology. 10. Swadeshi Innovation Award 2012 by the Swadeshi Science Movement, Kerala. 11. Sri Vidyadhiraja Samskrithi Puraskaram 2013 by Panmana Ashram, Quilon, Kerala. 12. CRSI Silver Medal 2013 by Chemical Research Society of India. 13. TWAS Chemistry Prize 2013 by The World Academy of Sciences, Trieste, Italy. 14. ISAS National Award for Excellence in Science and Technology 2014 by Indian Society of Analytical Scientists. 15. CHEMTECH CEW Award 2015 for Leadership and Excellence in Research and Development. 16. J. C. Bose National Fellowship, 2015, DST, Govt. India. 17. Web of Science-India Research Excellence-Citation Award 2017 by Clarivate Analytics. 18. MRSI Distinguished Lectureship Award, 2019-20, by Materials Research Society of India. 19. Goyal Prize for Chemical Science, 2019, by Kurukshetra University. Other Honors 1.
=== Pharmacokinetics === The oral bioavailability of clomipramine is approximately 50%. Peak plasma concentrations occur around 2–6 hours (with an average of 4.7 hours) after taking clomipramine orally and are in the range of 56–154 ng/mL (178–489 nmol/L). Steady-state concentrations of clomipramine are around 134–532 ng/mL (426–1,690 nmol/L), with an average of 218 ng/mL (692 nmol/L), and are reached after 7 to 14 days of repeated dosing. Steady-state concentrations of the active metabolite, desmethylclomipramine, are around 230–550 ng/mL (730–1,750 nmol/L). The volume of distribution (Vd) of clomipramine is approximately 17 L/kg. It binds approximately 97–98% to plasma proteins, primarily to albumin. Clomipramine is metabolized in the liver mainly by CYP2D6. It has a terminal half-life of 32 hours, and its N-desmethyl metabolite, desmethylclomipramine, has a terminal half-life of approximately 69 hours. Clomipramine is mostly excreted in urine (60%) and feces (32%). Although the normal maximum-recommended total daily dosage of clomipramine is 250 milligrams, treatment-resistant cases of depression and obsessive-compulsive disorder may require corresponding doses within the range of 255 to 300 milligrams. Indeed, doses of 375 milligrams per day, sometimes in combination with venlafaxine or aripiprazole, have not only been necessary but, remarkably, relatively well-tolerated.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.